The Therapeutic Goods Administration (TGA) have issued a product warning for the GLP-1 class of medicines and the potential risk of suicidal thoughts or behaviours.
For more information and the latest updates, see the TGA's medicine safety update for GLP-1 RA class.
The Therapeutic Goods Administration (TGA) also have issued a product warning about the reduced effectiveness of oral contraception during initiation or dose increases with Mounjaro (tirzepatide). For more information and the latest updates, see the TGA’s medicine safety update for Mounjaro (tirzepatide).
The medicine below contain the following active ingredient: tirzepatide
You can select a medicine from this list to find out more — including side effects, age restrictions, and whether the medicine is subsidised by the government on the pharmaceutical benefits scheme (PBS).
